The role of peroxisome proliferator-activated receptor gamma and adiponectin in children with Kawasaki disease

被引:4
|
作者
Zhang, Ji-Yong [1 ,2 ]
Peng, Hong [3 ]
Gong, Si-Tang [1 ]
Zeng, Yong-Mei [2 ]
Huang, Miao [2 ]
Liu, Pei-Hui [2 ]
Wang, Li-Ting [2 ]
Dong, Guo-Qing [2 ]
机构
[1] Jinan Univ, Affiliated Hosp 1, Dept Paediat, Guangzhou, Guangdong, Peoples R China
[2] Southern Med Univ, Affiliated Shenzhen Matern & Child Healthcare Hos, Dept Paediat, 2004 Hongli Rd, Shenzhen 518000, Guangdong, Peoples R China
[3] Shenzhen Peoples Hosp, Dept Infect Dis, Shenzhen, Guangdong, Peoples R China
关键词
Kawasaki disease; peroxisome proliferator-activated receptors gamma (PPARγ adiponectin; blood lipid; coronary artery lesion;
D O I
10.1177/0300060521994925
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective To investigate the relationship between peroxisome proliferator-activated receptor gamma (PPAR gamma) mRNA, serum adiponectin (ADP) and lipids in paediatric patients with Kawasaki disease (KD). Methods This prospective study enrolled paediatric patients with KD and grouped them according to the presence or absence of coronary artery lesions (CAL). A group of healthy age-matched children were recruited as the control group. The levels of PPAR gamma mRNA, serum ADP and lipids were compared between the groups. Receiver operating characteristic (ROC) curve analysis was undertaken to determine if the PPAR gamma mRNA level could be used as a predictive biomarker of CAL prognosis. Results The study enrolled 42 patients with KD (18 with CAL [CAL group] and 24 without CAL [NCAL group]) and 20 age-matched controls. PPAR gamma mRNA levels in patients with KD were significantly higher than those in the controls; but significantly lower in the CAL group than the NCAL group. ROC curve analysis demonstrated that the PPAR gamma mRNA level provided good predictive accuracy for the prognosis of CAL. There was no association between PPAR gamma, ADP and lipid levels. Conclusion There was dyslipidaemia in children with KD, but there was no correlation with PPAR gamma and ADP. PPAR gamma may be a predictor of CAL in patients with KD with good predictive accuracy.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Peroxisome proliferator-activated receptor gamma (PPARgamma) and oligodendroglioma.
    Paueksakon, P
    Parker, JR
    Johnson, MD
    Goodman, JC
    Powell, SZ
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2002, 61 (05): : 473 - 473
  • [42] The peroxisome proliferator-activated receptor α (PPARα):: role in hepatocarcinogenesis
    Gonzalez, FJ
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2002, 193 (1-2) : 71 - 79
  • [43] Peroxisome proliferator-activated receptor gamma and BRCA1
    Furth, Priscilla A.
    ENDOCRINE-RELATED CANCER, 2019, 26 (02) : R73 - R79
  • [44] Peroxisome Proliferator-Activated Receptor Gamma Involvement in Placenta Development
    Dominguez, Esteban M.
    Moreno, Ayelen
    Iqbal, Khursheed
    Soares, Michael J.
    REPRODUCTIVE SCIENCES, 2022, 29 (SUPPL 1) : 160 - 160
  • [45] Peroxisome proliferator-activated receptor-gamma ligands: Thiazolidinediones
    Zingarelli, B
    SHOCK, 2004, 21 : 126 - 126
  • [46] Peroxisome proliferator-activated receptor gamma: promising target in glioblastoma
    Gupta, Gaurav
    Singhvi, Gautam
    Chellappan, Dinesh K.
    Sharma, Sanjay
    Mishra, Anurag
    Dahiya, Rajiv
    de Jesus Andreoli Pinto, Terezinha
    Dua, Kamal
    PANMINERVA MEDICA, 2018, 60 (03) : 109 - 116
  • [47] The role of peroxisome proliferator-activated receptor γ in the progression of sepsis
    Schmidt, M. V.
    von Knethen, A.
    Bruene, B.
    WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 : 65 - 65
  • [48] ROLE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)-α IN SEPSIS
    Standage, S.
    Odoms, K.
    Denenberg, A.
    Zingarelli, B.
    Wong, H.
    SHOCK, 2010, 33 : 10 - 10
  • [49] Peroxisome proliferator-activated receptor gamma in human prostate carcinoma
    Nakamura, Yasuhiro
    Suzuki, Takashi
    Sugawara, Akira
    Arai, Yoichi
    Sasano, Hironobu
    PATHOLOGY INTERNATIONAL, 2009, 59 (05) : 288 - 293